The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer

The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer

Aims: This study investigated the impact of promoter methylation of flouropyrimidine (FP) metabolizing and cyclooxygenase 2 (COX2) genes on their mRNA expression and on the clinical outcome of colorectal cancer (CRC) patients. Methods: Methylation specific-PCR and real time-PCR of thymidylate syntha...

Full description

Bibliographic Details
Main Authors:	Mariam Ahmed Fouad, Salem Eid Salem, Marwa M. Hussien, Doaa Mohamed Badr, Abdelrahman N. Zekri, Hafez Farouk Hafez, Samia A. Shouman
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-02-01
Series:	Epigenetics Insights
Online Access:	https://doi.org/10.1177/2516865720986231

Similar Items

Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients
by: Mariam A. Fouad, et al.
Published: (2018-10-01)

The Prognostic Significance of 5-Fluorouracil Induced Inflammation and Immuno-Modulation in Colorectal Cancer Patients
by: Abdellateif MS, et al.
Published: (2020-12-01)

The Combination of α-Tocopheryl Succinate and Sodium Selenite on Breast Cancer: A Merit or a Demerit?
by: Doaa M. Badr, et al.
Published: (2016-01-01)

Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
by: Ching-Wen Huang, et al.
Published: (2021-07-01)

Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity
by: Saif MW
Published: (2020-10-01)

Fluoropyrimidine Modulation of the Anti-Tumor Immune Response―Prospects for Improved Colorectal Cancer Treatment
by: William H. Gmeiner
Published: (2020-06-01)

Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.
by: Barbara A Jennings, et al.
Published: (2013-01-01)

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
by: S Whyte, et al.
Published: (2010-10-01)

Heart rate sensor node analysis for designing internet of things telemedicine embedded system
by: Hafez Fouad, et al.
Published: (2017-01-01)

PHARMACOKINETIC STUDIES OF BETA-BLOCKERS AND FLUOROPYRIMIDINES.
by: SCHAAF, LARRY JOE.
Published: (1985)

Correction: evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.
by: Barbara A Jennings, et al.
Published: (2015-01-01)

Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer
by: Popov Ivan, et al.
Published: (2007-01-01)

Dihydropyrimidine dehydrogenase level and the redox status in patients with colorectal cancer are prognostic for adverse effects of fluoropyrimidines
by: Nadya G. Hristova-Avakumova, et al.
Published: (2021-01-01)

Aesthetic Management of Erosive Tooth Wear in a Young Egyptian Swimmer: A Case Report
by: Salem MN, et al.
Published: (2021-05-01)

Significance of cyclooxygenase-2 in oncogenesis
by: Szweda Marta, et al.
Published: (2019-06-01)

Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients
by: Xianwei Mo, et al.
Published: (2020-01-01)

Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis
by: Ellen Frejborg, et al.
Published: (2020-12-01)

Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients
by: Reza Negarandeh, et al.
Published: (2020-06-01)

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms
by: Xunwei Deng, et al.
Published: (2020-12-01)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
by: Dae-Won Lee, et al.
Published: (2019-05-01)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
by: Yeong Hak Bang, et al.
Published: (2021-03-01)

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy
by: Park Cheol, et al.
Published: (2011-08-01)

Cyclooxygenase and lipoxygenase as factors in colorectal cancer progression
by: Wilson, Jeremy Ian
Published: (2007)

Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy
by: Masier Sara, et al.
Published: (2004-03-01)

Cyclooxygenase-2 (cox-2) expression in Barrett's oesphageal epithelium : relationship to inflammation and cancer
by: Abdalla, Salem Ishtiwi
Published: (2005)

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study
by: Federica Martorana, et al.
Published: (2017-11-01)

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
by: Elena De Mattia, et al.
Published: (2018-10-01)

Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells
by: Ganesh Radhakrishnan, et al.
Published: (2012-09-01)

Leptin influences estrogen metabolism and increases DNA adduct formation in breast cancer cells
by: Samia Shouman, et al.
Published: (2016-12-01)

Performance optimization of energy harvesting solutions for 0.18um CMOS circuits in embedded electronics design
by: Hafez Fouad
Published: (2020-01-01)

Cyclooxygenase-2 and its role in angiogenesis in colorectal cancer
by: McArthur, David
Published: (2007)

Correlation of β-Catenin Localization with Cyclooxygenase-2 Expression and CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer
by: Takako Kawasaki, et al.
Published: (2007-07-01)

DPD status and fluoropyrimidines-based treatment: high activity matters too
by: Emmanuel Chamorey, et al.
Published: (2020-05-01)

Overexpression of p67phox in Response to Fluoropyrimidines in HCT116 Cells
by: Ufuk Ozer, et al.
Published: (2016-12-01)

Folinic Acid Enhanced Cytotoxicity of Fluoropyrimidines In Human Breast Cancer Cells
by: Mandelbaum-Shavit Frederika
Published: (1993-02-01)

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01)

The role of cyclooxygenase-2 in colorectal cell transformation and tumour progression
by: Kouveli, Angeliki
Published: (2002)

The effect of cyclooxygenase-2 inhibition on colorectal cancer liver metastases
by: Fenwick, Stephen William
Published: (2005)

Role of cyclooxygenases COX-1 and COX-2 in modulating adipogenesis in 3T3-L1 cells
by: Hongyun Yan, et al.
Published: (2003-02-01)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
by: Lili Wu, et al.
Published: (2021-09-01)